| Zanni, Manuela |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
| Active, not recruiting | 3 | 128 | Europe | R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R) | Fondazione Italiana Linfomi - ETS | Lymphoma, Follicular | 01/23 | 12/27 | | |
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 04/27 | 04/29 | | |
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
| Recruiting | N/A | 350 | Europe | | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 12/25 | 12/25 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial |
|
|
| Recruiting | N/A | 654 | Europe | EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 06/25 | 06/26 | | |
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma |
|
|
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | 12/27 | 12/27 | | |
NCT05524298: Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Low Grade Non-Hodgkin's Lymphoma, Adult | 02/25 | 02/25 | | |
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis |
|
|
| Recruiting | N/A | 400 | Europe | Treatment for clinical practise | Fondazione Italiana Linfomi ONLUS | Classical Hodgkin Lymphoma | 01/26 | 01/26 | | |
